



We want to save patients with severe cancer and autoimmune diseases

*Göran Forsberg, CEO*  
*Oct 2022*

**NASDAQ STOCKHOLM MAIN LIST (CANTA.ST)**


# Safe Harbor Statement




*Statements in the Investor Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors as they relate to events and depend on circumstances that will or may occur in the future, whether or not outside the control of the Company. No assurance is given that such forward-looking statements will prove to be correct. Prospective investors should not place undue reliance on forward-looking statements. They speak only as at the date of this Investor Presentation and the Company undertakes no obligation to update these forward-looking statements. Past performance does not guarantee or predict future performance. Moreover, the Company undertakes no obligation to review, update or confirm expectations or estimates or to release any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of the Investor Presentation.*

# Cantargia - strategy to improve current cancer therapies .....with support from clinical data

- Most chemotherapies induce resistance already after a few months of therapy
- Chemotherapy can upregulate both IL-1 $\alpha$  and IL-1 $\beta$  signaling through IL1RAP



Data in pancreatic cancer indicate synergy and clinical efficacy



SEVERAL LINES OF EVIDENCE SUGGEST CAN04 COUNTERACT CHEMORESISTANCE  
IL1RAP FOUND IN MOST SOLID TUMORS

# Cantargia – the IL1RAP company



## FIRST IN CLASS INNOVATIVE ANTIBODY THERAPIES AGAINST NOVEL IL1RAP TARGET

- Strong clinical interim results
- Next step randomized/registration trials based on more than 200 patients
- Platform to fill pipeline



## PLATFORM WITH BROAD POTENTIAL TO ADDRESS HIGH UNMET NEEDS

- Target IL1RAP found on most solid tumor forms and leukemias
- IL1RAP signalling key in large number of inflammatory diseases beyond oncology
- Robust patent portfolio on antibody target in oncology (to 2032) and lead asset (to 2035)



## INGREDIENTS FOR SUCCESS

- Solid cash position (350 MSEK, 33 MUSD end Q2 2022), plus rights issue for 250 MSEK
- Clear development plan with multiple upcoming catalysts
- Strong management team with experience in bringing products through development to market



# Cantargia – Save lives and create value through IL1RAP

Project	Disease	Type of treatment	Discovery phase	Preclinical phase	Clinical phase I	Clinical phase II	Clinical phase III	Commercial phase
CAN04 Nadunolimab	PDAC	1 <sup>st</sup> line	Gemcitabine/nab-paclitaxel					
			FOLFIRINOX					
	NSCLC/ non-squamous NSCLC	1 <sup>st</sup> /2 <sup>nd</sup> line	Platinum doublets					
		2 <sup>nd</sup> /3 <sup>rd</sup> line	Docetaxel					
	TNBC	1 <sup>st</sup> /2 <sup>nd</sup> line	Carboplatin/gemcitabine					
	Solid tumors	1 <sup>st</sup> line	Cisplatin/gemcitabine or FOLFOX					
		ICI combo	Pembrolizumab					
CAN10	Myocarditis; Systemic sclerosis							
CANxx	New opportunities within IL1RAP platform							

■ active, recruiting; ■ active, not recruiting; ■ non-clinical project; PDAC, pancreatic cancer; NSCLC, non-small cell lung cancer; TNBC, triple-negative breast cancer; ICI, immune checkpoint inhibitor

- Potentially more effective treatment against novel target in clinically validated pathway
- First in class platform technology against novel target
- Well-financed to build a broad, diversified pipeline
- Right team and clear plan to position our projects and maximize value

# Nadunolimab mechanism uniquely enhances docetaxel antitumor activity



Nadunolimab with docetaxel in MC38 syngeneic model:

- Nadunolimab blocks both IL-1 $\alpha$  and IL-1 $\beta$  and has ADCC activity
- Nadunolimab increases efficacy of docetaxel
- Control antibody blocking only IL-1 $\beta$  does not have the same effect
- Docetaxel increases IL-1 $\alpha$  production in vitro
- Highlights importance of blocking both forms of IL-1 to increase docetaxel efficacy

**IN CONTRAST TO IL-1 $\beta$  BLOCKADE, NADUNOLIMAB INCREASES DOCETAXEL EFFICACY;  
CLINICAL INVESTIGATION ONGOING**



# Combination strategy in NSCLC – Promising efficacy


Efficacy parameter*	All (n=30)**	Non-squamous (n=16)	Squamous (n=13)
ORR [95% CI]	53% [34-72]	56% [30-80]	46% [19-75]
Disease control rate*** (CR+PR+SD) [95% CI]	83% [65-94]	75% [48-93]	92% [64-100]
Median duration of response [95% CI]	5.8 months [3.7-11.2]	11.2 months [NA]	4.1 months [3.4-5.8]
PFS [95% CI]	6.8 months [5.5-8.8]	7.3 months [5.3-13.0]	5.8 months [3.7-7.4]
Median OS [95% CI]	13.7 months**** [NA]	NA	NA
1-year survival [95% CI]	53%**** [26-73%]	NA	NA

\*Responses according to RECIST1.1 criteria

\*\*One tumor of unknown histology

\*\*\*Two patients withdrew early in association with COVID-19

\*\*\*\*Based on 37% of events



**STRONG INTERIM RESULTS, UPDATE AT ASCO 2022**

Nadunolimab combination with Gem/Cis in 1<sup>st</sup> line:

- 16/30 patients showed objective response including 1 complete response (ORR 53% vs historical control data of 22-28%), 7pts still on treatment
- No major side effects observed except those from chemotherapy or nadunolimab alone. *Neutropenia frequency higher than expected from chemo (but can be treated with dose reductions or G-CSF)*
- Trial expanding – up to 40 additional patients with non-squamous NSCLC

<sup>1</sup> Schiller et al, N Engl J Med 2002

<sup>2</sup> Scagliotti et al, J Clin Oncol 2008




<sup>3</sup> Gandhi et al, N Engl J Med 2018

<sup>4</sup> Paz-Ares et al, N Engl J Med 2018

# Positive interim data in pancreatic cancer

Nadunolimab combination with Gem/Abraxane in 1<sup>st</sup> line (ASCO 2022), n=73:


- 33% response rate with durable responses
- Pseudoprogression-like response in 5 (7%) additional patients
- Promising PFS (7.2 mo) and OS (12.7 mo, 42 % events)
- 12 pts on treatment



PFS AND OS LONGER THAN EXPECTED GIVEN HISTORICAL CONTROL



# Cantargia addresses NSCLC & PDAC



## Non-Small Cell Lung Cancer



**2.1m** Annual global incidences

**12%** Fraction of cancer incidence

**1.8m** Annual global mortalities

**18%** Fraction of cancer mortality

**19%** Five-year survival rate

**Treatment:** Surgery, Radiation, Chemotherapy, Immunotherapy

## Pancreatic cancer



**0.5m** Annual global incidences


**3%** Fraction of cancer incidence

**0.4m** Annual global mortalities

**5%** Fraction of cancer mortality

**9%** Five-year survival rate


**Treatment:** Chemotherapy, Surgery, Radiation



SIGNIFICANT UNMET NEEDS IN LUNG AND PANCREATIC CANCER  
BILLION DOLLAR MARKETS IN CANTARGIA SEGMENTS


# CAN10 – New asset within autoimmunity/inflammation

- IL1RAP binding antibody potentially blocking IL-1, IL-33 and IL-36
- Unique anti-inflammatory activity observed in different mouse models (myocarditis, systemic sclerosis, psoriasis, inflammation)
- Development focusing on unmet medical need in systemic sclerosis and myocarditis. Disease selection in collaboration with experts based on scientific rationale, medical need, development opportunity and competition.
- Clinical trial starts early 2023





UNIQUE OPPORTUNITY FOR CAN10 IDENTIFIED IN LIFE-THREATENING DISEASES



# CAN10 – Unique properties in preclinical disease models





## Systemic sclerosis model



## Myocarditis - Treatment from day 7 Left Ventricular Ejection Fraction



## New data showing efficacy in viral myocarditis



CAN10 shows potential in several autoimmune/inflammatory diseases with high medical need  
Phase I planned for early 2023

# Several upcoming value inflection points

## Newsflow over next 6-9 months

### *Nadunolimab (CAN04)*

- Update of results for PDAC, NSCLC and Keytruda combination presented at ASCO
- Phase 2/3 Precision Promise (PDAC)
- New preclinical and translational results
- New clinical trials (efficacy and safety)
  - CAPAFOUR PDAC FOLFIRINOX
  - CESTAFOUR Basket trial (NSCLC, CRC, BTC)
  - TRIFOUR TNBC

### *CAN10*

- Preclinical progress
- Development milestones
- ...and initiation of clinical trial early 2023



**SIGNIFICANT DATA TO SECURE NEWSFLOW**